Background: Injectable therapy is required when patients with Type 2 Diabetes do not achieve glycemic control despite previous dietary and lifestyle modifications combined with oral antidiabetic therapy. The objective of this study was to compare socio-demographic and clinical characteristics of patients who initiated insulin versus glucagon like peptide-1 injectable therapy (GLP-1 RA) in a real world setting.
Methods: All patients who initiated insulin or GLP-1 therapy in 2010-2014 were identified in the Clalit data warehouse. Socio-demographic, clinical, and concurrent medication data were extracted in prior proximity to the time of therapy initiation (index-date).
Results: A total of 49,807 patients were identified: 41,049 receiving insulin and 8,758 GLP-1 RA. The duration of diabetes prior to injectable therapy initiation was similar (8 years). Insulin initiators, compare to GLP-1 RA initiators, were older (age 63 vs. 58); less obese [mean BMI: 29.0 (95% CI: 25.7-32.9) vs. 34.6 (95% CI: 31.6-38.4)]; had higher Charlson Comorbidity Index (47% vs. 30% index ≥5) and were more likely to have HgbA1c >9.0% (50% vs. 38%), all comparisons p<.05.
Conclusions: Clear differences were identified in the population prescribed insulin compared to that prescribed GLP-1 RA. Analyses are ongoing to further understand the impact of these characteristics on glycemic control and other outcomes among these individuals.
Disclosures: This study was supported and conducted by Eli Lilly and Company, Indianapolis, IN, USA. This is an encore of an abstract that was presented at International Society for Pharmacoeconomics and Outcomes Research - 22nd Annual International Meeting, May 20 – 24, 2017; Boston, MA, USA.